NVRO241220P2500
- 0.05
- 0.000.00%
Nevro Newsroom
Citigroup Maintains Neutral on Nevro, Lowers Price Target to $5
Nevro Is Maintained at Equal-Weight by Wells Fargo
Citi Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $5
Zacks.com Featured Highlights Include Stryve Foods, Nevro, Canoo, MSA Safety and VTEX
Nevro Is Maintained at Hold by Canaccord Genuity
Nevro Price Target Cut to $4.00/Share From $7.00 by Canaccord Genuity
Wells Fargo Upgrades Nevro(NVRO.US) to Hold Rating, Cuts Target Price to $5
Express News | Wells Fargo Reinstates Equal-Weight on Nevro, Announces $5 Price Target
Nevro Corp: Hold Rating Amid Market Challenges and Strategic Uncertainty
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley Downgrades Nevro to Underweight, Lowers Price Target to $4
Nevro Analyst Ratings
Morgan Stanley Downgrades Nevro(NVRO.US) to Sell Rating, Cuts Target Price to $4
Nevro's SI Joint Fixation System Delivers Enhanced Stability and Fusion for Patients
NVRO Stock Declines Despite Positive Study Data of Nevro1 System
New Study Demonstrates Multiple Advantages of Nevro1, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Stock May Gain on the CE Mark Certification for HFX IQ
Express News | Engaged Capital LLC Cuts Share Stake in Nevro Corp to 1.5% as of Nov 12 - SEC Filing